Sofwave is a company.
Key people at Sofwave.
Sofwave was founded by Shimon Eckhouse (Co founder and chairman).
Sofwave Medical Ltd. is a regenerative aesthetics company developing non-invasive, FDA-cleared medical devices using proprietary ultrasound and EMS technologies for skin lifting, toning, wrinkle reduction, and laxity improvement.[1][2][4][7] Its flagship SUPERB™ (Synchronous Ultrasound Parallel Beam) technology targets facial lines, eyebrow and submental lifting, upper arm laxity, cellulite, and acne scars, while the Pure Impact™ module provides muscle toning via PlyoPulse™ EMS, serving aesthetic practitioners and patients seeking needle-free alternatives to surgery.[2][3][4][7] The company solves the demand for effective, downtime-free skin rejuvenation amid rising interest in non-invasive treatments, fueled by trends like GLP-1 obesity drugs increasing skin tightening needs, with over 460,000 treatments delivered and 19% full-year 2024 revenue growth (recurring revenue up 79%).[2][3]
Founded in 2016, Sofwave Medical set out to revolutionize aesthetics with non-invasive solutions, led by Dr. Shimon Eckhouse, Chairman and co-founder, an industry veteran with expertise in energy-based devices.[2][3][4] The idea emerged from leveraging deep team knowledge to create SUPERB™ technology, launching commercially in 2020 and achieving rapid adoption with a compound annual revenue growth rate of 85% since then.[3] Pivotal moments include multiple FDA clearances (e.g., upper arm laxity and Pure Impact™ in 2023-2024), over 225,000 treatments by end-2023 scaling to 460,000 by 2024, and appointing experts like Chief Innovation Officer James Bartholomeusz.[2][3]
Sofwave rides the explosive growth in non-invasive aesthetics, a market boosted by GLP-1 drugs (e.g., for obesity) creating post-weight-loss skin laxity demand, alongside consumer preference for zero-downtime regenerative treatments.[2][3] Timing is ideal amid industry headwinds, as its needle-free ultrasound outperforms lasers/surgery in safety, efficacy, and accessibility, with global KOL traction and 19% revenue growth despite macro challenges.[1][2] It influences the ecosystem by setting standards for energy-based devices, expanding practitioner tools via partnerships, and accelerating adoption through proven results (460K+ treatments), positioning non-invasive tech as the future over invasive alternatives.[1][3][7]
Sofwave is primed for accelerated growth toward industry leadership in non-invasive aesthetics, with Q4 2024 earnings highlighting strong momentum and profitability on the horizon via lean ops and expanding indications.[1][2] Trends like obesity treatments and rising brand awareness (1M+ followers) will drive demand; expect more clearances, international expansion, and module innovations to solidify its edge.[1][2][3] As it scales from 2020 launch success, Sofwave could redefine regenerative skin tech, delivering sustained shareholder value in a high-margin, patient-centric market—revolutionizing aesthetics one needle-free lift at a time.[2][4]
Key people at Sofwave.
Sofwave was founded by Shimon Eckhouse (Co founder and chairman).
